801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOral Medications

Telmisartan Tablets 20mg, 40mg, 80mg Oral Medications

Telmisartan Tablets 20mg, 40mg, 80mg Oral Medications

Telmisartan Tablets 20mg, 40mg, 80mg Oral Medications

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 20mg, 40mg, 80mg

Payment & Shipping Terms:

Minimum Order Quantity: 500, 000 tablets
Price: Negotiation
Packaging Details: 10’s/blister
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: One million pills per day
Contact Now
Detailed Product Description
Product: Telmisartan Tablets Specification: 20mg, 40mg, 80mg
Standard: BP, USP Packing: 10’s/blister

Telmisartan Tablets 20mg, 40mg, 80mg Oral Medications

 

Product : Telmisartan Tablets

Specification : 20mg, 40mg, 80mg

Standard : BP, USP

Packing : 10’s/blister

 

Description :

Telmisartan tablet is a non-peptide angiotensin II receptor (type AT1) antagonist.

Telmisartan available as tablets for oral administration, containing 20 mg, 40 mg or 80 mg of telmisartan.

 

Indications and Usage :

1. Hypertension

Telmisartan Tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program`s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

It may be used alone or in combination with other antihypertensive agents.

 

2. Cardiovascular Risk Reduction

Telmisartan Tablets is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.

High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage. Telmisartan Tablets can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).

Studies of telmisartan in this setting do not exclude the possibility that telmisartan may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)